Eugenio Gaudio

List of Publications by Year
in descending order

33	954	516710 16	454955 30
papers	citations	h-index	g-index

33	33	33	1829
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Advances, 2021, 5, 2467-2480.	5.2	10
2	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. Exploration of Targeted Anti-tumor Therapy, 2021, 2, 586-601.	0.8	3
3	Pyrrolo[2â€²,3â€²:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types. Journal of Medicinal Chemistry, 2020, 63, 12023-12042.	6.4	43
4	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Advances, 2020, 4, 4124-4135.	5.2	37
5	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Advances, 2020, 4, 819-829.	5.2	28
6	Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. European Journal of Medicinal Chemistry, 2019, 181, 111545.	5.5	13
7	Single and combined BTK and PI3KÎ´ inhibition with acalabrutinib and ACPâ€319 in preâ€clinical models of aggressive lymphomas. British Journal of Haematology, 2019, 187, 595-601.	2.5	12
8	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica, 2019, 104, e307-e309.	3.5	14
9	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers, 2019, 11, 775.	3.7	14
10	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clinical Cancer Research, 2019, 25, 5167-5176.	7.0	43
11	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. Molecular Cancer Therapeutics, 2019, 18, 1255-1264.	4.1	27
12	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica, 2019, 104, 1633-1639.	3.5	28
13	Fhitâ€“Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells. Cell Death and Disease, 2019, 10, 147.	6.3	35
14	In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas. British Journal of Haematology, 2019, 186, 149-152.	2.5	3
15	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica, 2019, 104, e256-e259.	3.5	43
16	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. Blood, 2019, 134, 2569-2569.	1.4	3
17	<scp>TCL</scp>1A interacts with <scp>TP</scp>63 and enhances the survival of Raji Burkitt lymphoma cell line. British Journal of Haematology, 2018, 183, 509-512.	2.5	6
18	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	7.0	92

#	Article	IF	Citations
19	Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach. PLoS ONE, 2018, 13, e0208709.	2.5	6
20	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open, 2018, 3, e000387.	4.5	21
21	T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. Frontiers in Oncology, 2018, 8, 317.	2.8	23
22	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica, 2018, 103, 2049-2058.	3.5	13
23	Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors. Blood, 2018, 132, 4174-4174.	1.4	3
24	New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease. Blood, 2018, 132, 4173-4173.	1.4	0
25	Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma. British Journal of Haematology, 2017, 178, 936-948.	2.5	42
26	The Fhit protein: an opportunity to overcome chemoresistance. Aging, 2016, 8, 3147-3150.	3.1	4
27	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strongin vivoantitumor activity in lymphoma. Oncotarget, 2016, 7, 58142-58147.	1.8	25
28	A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells. Oncotarget, 2016, 7, 29927-29936.	1.8	16
29	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical Cancer Research, 2015, 21, 1628-1638.	7.0	237
30	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. Oncotarget, 2015, 6, 5059-5071.	1.8	29
31	Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood, 2013, 121, 351-359.	1.4	15
32	Fhit Delocalizes Annexin A4 from Plasma Membrane to Cytosol and Sensitizes Lung Cancer Cells to Paclitaxel. PLoS ONE, 2013, 8, e78610.	2.5	18
33	Tcl1 interacts with Atm and enhances NF-ÎºB activation in hematologic malignancies. Blood, 2012, 119, 180-187.	1.4	48